

Journal Pre-proof

Practical Guidelines for the Evaluation and Management of Drug Hypersensitivity:
General Concepts

Ana Dioun Broyles, MD, Aleena Banerji, MD, Mariana Castells, MD PhD



PII: S2213-2198(20)30812-6

DOI: <https://doi.org/10.1016/j.jaip.2020.08.002>

Reference: JAIP 3042

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*

Received Date: 7 August 2020

Accepted Date: 7 August 2020

Please cite this article as: Broyles AD, Banerji A, Castells M, Practical Guidelines for the Evaluation and Management of Drug Hypersensitivity: General Concepts, *The Journal of Allergy and Clinical Immunology: In Practice* (2020), doi: <https://doi.org/10.1016/j.jaip.2020.08.002>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

**Practical Guidelines for the Evaluation and Management of Drug Hypersensitivity:
General Concepts**

Authors: Ana Dioun Broyles^a, MD, Aleena Banerji^b, MD and Mariana Castells^c, MD PhD

- a. Division of Allergy/Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA
- b. Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
- c. Drug hypersensitivity and Desensitization Center, Brigham and Women's Hospital, Harvard Medical School , Boston, MA

The authors have no conflicts of interest regarding this work

CORRESPONDING AUTHOR:

Ana Dioun Broyles, MD
Boston Children's Hospital
300 Longwood Ave.
Boston, MA 02115
Phone: 617 355 6117
email: ana.broyles@childrens.harvard.edu

Introduction

Comprehensive practical guidelines for the evaluation and management of patients with drug allergy and hypersensitivity are lacking. The authors have aimed to create such a document that draws primarily from evidence-based published literature and incorporates experience from experts to fill this current knowledge gap and to expand the scope of practice for allergist/immunologists.

The document that follows first reviews the epidemiology, standardized terminology, and classification of drug hypersensitivity reactions, as these are critical steps in understanding drug allergy. It then discusses the initial assessment of patients with drug hypersensitivity, gained by obtaining a thorough history, and important points pertinent to the physical examination. It summarizes the knowledge that guides diagnostic steps such as skin testing and drug challenges. Finally, the authors review protocols for drug hypersensitivity management using desensitization for both adult and pediatric patients, and the appropriate steps required for safe application of these protocols. This general section is the preamble for the Specific Drugs Section which discusses published data, clinical experience, and recommendations for each class of drugs.

Epidemiology of Drug Hypersensitivity

Adverse drug reactions (ADRs) are estimated to account for 3% to 6% of all hospital admissions and to occur in 10% to 15% of hospitalized patients resulting in morbidity, prolonged hospitalization and increased risk of mortality.(1) Although most of these reactions are due to predictable and dose-dependent effects of drugs, 10-20% of ADRs, including allergic drug reactions, are unpredictable and dose-independent.(2)(3)

Allergic drug reactions are also known as hypersensitivity reactions and account for about 6% to 10% of all ADRs. In children, drug allergy has also been reported with a relatively high frequency, occurring in up to 8.7% of pediatric patients in varied hospital settings and 1% to 8% of visits in outpatient pediatric offices. (4)

From 2001 to 2012, the estimated incidence for emergency department visits for patients with allergic drug reactions rose from 0.49% to 0.94%.(5) In a recent review from Brazil, drug allergy accounted for 40%-60% of emergency room anaphylactic reactions. When 806 patients presenting with drug allergy were screened, 117 (14.5%) had been diagnosed with anaphylaxis, and fewer than 34.2% of those patients had received epinephrine.(6) The increased incidence of allergic drug reactions is consistent with an increased incidence of overall allergic sensitization in the population, including reactions to foods and other allergens.

Classification of Drug Hypersensitivity

Allergic drug reactions are distinguished from other unpredictable adverse drug reactions in that they are mediated by an immunologic mechanism. No single classification scheme permits the categorization of all allergic drug reactions. They are currently categorized using the somewhat

dated Gell and Coombs's classification into four types of hypersensitivity reactions:

Type I: Immediate reactions mediated by IgE antibodies leading to mast cell and basophil degranulation with symptoms ranging from urticaria to anaphylaxis. At this time, Type I drug reactions also include those involving the activation of mast cells and basophils through non-IgE mechanisms

Type II: Cytotoxic IgM- or IgG-mediated reactions against a cell surface antigen, such as drug-induced hemolytic anemia

Type III: Immune complex deposition reactions with activation of complement, such as serum sickness-like reactions

Type IV: Delayed T-lymphocyte-mediated reactions, such as contact dermatitis and delayed maculopapular rashes. Subcategorization of Type IV reactions into a, b, c, and d reactions has expanded the scope of Type IV delayed reactions to include those for which the mechanism and cellular targets are not completely understood and may involve cells other than T cells.(7)

There are shortfalls to such a system. Some allergic drug reactions cannot be classified due to a lack of insight into the underlying mechanism, or the mechanism is known but it does not fall into the existent classification scheme. Acute reactions to taxanes can trigger mast cell/basophil activation with elevation of serum tryptase with or without evidence of IgE, and they are currently considered Type I reactions and amenable to desensitization.(8) Hypersensitivity to rituximab and other monoclonal antibodies can present as mixed patterns of type I and "cytokine-storm-like" reactions with chills, fever, generalized malaise, flushing, and hypotension, and can be associated with elevations of tryptase and IL-6 in serum.(9, 10) Patients presenting with such reactions may have positive skin testing, demonstrating that IgE plays a role in the mixed immune mechanisms.(11, 12) These mixed reactions may be amenable to desensitization and, depending on the indications, will require careful evaluation of symptoms and adjusted protocols with premedications.

Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), drug hypersensitivity syndrome/drug reactions with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP); as well as interstitial nephritis, drug fever, vasculitis, and hepatitis are considered type IV reactions and are currently a formal contraindication for desensitization. The safety and efficacy of desensitization for these reactions is unknown at this time.(13-15) Aromatic anti-convulsants can induce DRESS, which is also known as anti-convulsant hypersensitivity syndrome, and cross-reactivity among anti-convulsants sharing aromatic rings is very high and thought to be due to specific HLA phenotypes. In these cases, small amounts of a medication can induce severe symptoms and desensitization is contraindicated.(16) In contrast, reactions presenting as maculopapular rashes without systemic involvement are considered potentially amenable to graded challenge or desensitization.

A 2017 Practical Allergy Report (PRACTALL) document from a consensus precision medicine initiative between the American Academy of Asthma Allergy and Immunology (AAAAI) and the European Academy of Allergy and Clinical Immunology (EAACI) has provided an inclusive definition of drug allergy to encompass phenotypes, endotypes, and molecular markers.(17) This broader categorization, bridging clinical presentations and symptoms, provides useful tools for a better understanding of underlying mechanisms of allergy and helps personalized recommendations.(17) Drug allergy phenotypes are classified as immediate-onset or delayed onset. Immediate onset drug allergy includes symptoms within 1 to 6 hours of exposure that are not limited to IgE-mediated reactions or direct mast cell/basophil activation and can occur with or without previous drug exposure. Delayed-onset drug allergy can occur days to weeks after allergen exposure and can present with heterogeneous symptoms due to isolated single-organ involvement or systemic multi-organ involvement. Endotypes responsible for immediate and delayed drug reactions include IgE and direct mast cell activation, cytokine release, T cell mediation, and genetic predisposition associated with specific HLA phenotypes, among additional mechanisms. Biomarkers of drug allergy include specific IgE and tryptase levels and can be identified using skin testing, basophil activation test, and other approaches.

Risk Factors for Drug Hypersensitivity

Females have a higher risk for drug hypersensitivity reactions, and the mechanisms underlying this propensity are not fully understood.(18, 19) Cyclical hormonal changes are thought to be the basis for progestogen hypersensitivity syndromes (formerly progesterone autoimmune dermatitis), in which either progesterone-like hormones that are endogenous or exogenous during in vitro fertilization treatments or estrogens serve as sensitizing allergens that can induce reactions ranging from dermatitis to anaphylaxis.(20, 21) Environmental chemicals containing quaternary ammonium compounds found in products such as cosmetics and detergents are thought to be cross-reactive with neuromuscular blocking agents and opioids and therefore may increase the risk of reactions during general anesthesia.(20)(22, 23)

Patients with cancer or cystic fibrosis are likely at higher risk of drug hypersensitivity as well. Atopy has been shown to be a risk factor for the development of drug hypersensitivity in cancer patients exposed to taxenes.(24) Increased IgE sensitization to drug allergens has been observed in patients with multiple drug allergies.(25)(26) In women with ovarian cancer IgE-mediated hypersensitivity reactions to carboplatin occur in up to 27% of the patients after six or more treatments and earlier in patients with *BRCA* mutations.^(27, 28) The risk of a patient reacting to multiple drugs with unrelated allergenic epitopes is infrequent for IgE mediated reaction but has been described for type IV reactions.(29, 30) T-cell clones isolated from drug allergic patients with cystic fibrosis were found to proliferate and release cytokines following stimulation with piperacillin, meropenem, or aztreonam and cross-reactivity with the different drugs was not

observed indicating specific T-cell responses to 3 different antigenic determinants.⁽³¹⁾

The drugs most commonly implicated in type I reactions in patients with cystic fibrosis are penicillins and cephalosporins.(32, 33) Overall allergic reactions to antibiotics are more common in cystic fibrosis (CF) patients than in the general population. This is due in part to the improving survival of these patients as well as the increased use of high dose intravenous antibiotics. While some are immediate anaphylaxis type (IgE-mediated) reactions, the majority are late onset and may have non-specific features such as rash and fever.

Heterologous responses to viral infections in the context of specific HLA alleles have been implicated as novel mechanisms associated with SCARs.(13, 34) Pathogen-directed T effector memory cells induce heterologous immune responses that can modify T cell-mediated immunity. Human herpesvirus, CMV, and some other viruses can establish lifelong subclinical infections and cellular latency, with periodic transcriptional reactivation of the virus resulting in viral proteins that stimulate virus-specific T cell memory. In that context, the induction of drug hypersensitivity requires an HLA risk allele, a primary infection with human herpesvirus or another virus, and a polyclonal expansion of CD8+ T memory cells. Upon drug exposure, the interaction with specific HLAs induces the generation of neoantigens recognized by the CD8+ T memory cells. These reactions can occur at first exposure and do not require sensitization.(35, 36)

HLA risk alleles are key to the viral responses and the antiretroviral drug abacavir has exemplified their importance, as it induces severe hypersensitivity reactions in individuals expressing HLA-B*5701. Patch testing with abacavir is positive before systemic abacavir exposure in HLA-B*5701-positive individuals (approximately 5% of those of European ancestry, 1% of those of Asian ancestry, and <1% of those of African ancestry) due to the local skin T cell activation that results from abacavir binding to HLA-B*5701. Other risk alleles have been identified and associated with susceptibility to aromatic anticonvulsants and reactions to allopurinol and sulfonamides.(37, 38) Genotyping for drug susceptibility can identify potential reactors and aid in protecting at risk populations, but this recommendation is currently limited to a few drugs.(17)

Evaluation of Patients with Suspected Drug Hypersensitivity (Figure 1)

History: A thorough history is essential in the evaluation of patients with suspected drug allergy.(39)(4) Whenever possible, the medical records should be carefully reviewed. Some important questions to address when obtaining the history are listed below:

1. What were the names of each of the suspected medications and how long ago did the reaction occur?

Patients often may not remember the medications they received, and this is especially the case if multiple medications were given simultaneously, for example, in an intensive care unit or operating room. In these cases, reviewing the medical records becomes critical. It is important to consider that patients may experience reduced drug sensitivity over time.

2. Was this the patient's first exposure to the medication?

An IgE-mediated reaction typically does not occur with the first exposure although the possibility of exposure in utero or while breastfeeding should be considered, particularly with younger children. As mentioned earlier, quaternary ammonium compounds present in cosmetics are thought to be cross-reactive with neuromuscular blocking agents and increase the risk of reactions during general anesthesia. Cross reactivity between paclitaxel, with hazelnut and tree pollen, has been suggested as the cause of reactions at first or second exposure in cancer patients.(40)

3. What was the underlying condition for which the medication(s) were prescribed?

The underlying condition, such as a viral syndrome, may be the cause of skin rash or possibly other symptoms. For example, patients with *Mycoplasma pneumoniae* infection can develop acute urticaria or Stevens-Johnson Syndrome.(41, 42) In addition, patients with infectious mononucleosis are more likely to react to ampicillin,(43) and patients with HIV infection are more likely to react to trimethoprim-sulfamethoxazole.(44)

4. What were the symptoms and signs of the reaction, and what was the timing relative to when the patient received the medication?

Certain symptoms and signs such as urticaria and pruritus, particularly if they occur less than an hour after receiving a medication, would be more suggestive of an IgE- or non-IgE-mediated immediate reaction. This is in contrast to a T-cell mediated reaction, which presents with different symptoms and is often delayed in nature. Cancer patients premedicated with antihistamines may not describe symptoms of pruritus during an IgE-mediated reaction and may present with delayed symptoms due to the premedication regimen's masking of the side effects.

5. If other drugs were concomitantly administered, what was the timing of each symptom and/or sign in relation to the administration of each medication?

This may help determine which drug or drugs were more likely to have been associated with the reaction. In the example of perioperative anaphylaxis, the record of the exact time of introduction of each medication should be reviewed at the time of allergy evaluation. It is similarly important to check whether narcotics and NSAIDS were administered, as these drugs can trigger pruritus

and potentially rash as a result of scratching and/or dermatographism. This could otherwise be mistaken as symptoms of IgE-mediated allergy.

6. Has the patient received any of the medications or a related combination medication since the initial reaction, and were there any reactions associated with the most recent exposure?

If there was no reaction with the repeat administration of the drug or a related combination drug, it is unlikely that the drug being considered was the cause of the initial reaction (e.g., a patient who has tolerated amoxicillin/clavulanate after a history of amoxicillin allergy is unlikely to be allergic to either amoxicillin or clavulanate).

7. Has the patient experienced similar symptoms/signs in the absence of the culprit medication (s)?

In these cases the patient's primary condition could be the trigger for the symptoms/signs rather than drug exposure, such as urticaria in a patient with chronic urticaria.

8. How long after the drug was discontinued did the reaction resolve, and did the reaction seem to respond to factors other than discontinuing the drug? Did some of the interventions fail?

A faster resolution suggests IgE or mast cell involvement. An immediate response to antihistamines and/or epinephrine might also suggest an IgE-mediated or mast cell reaction and a lack of response makes such mechanisms less likely. Benign rashes that persist for months or years are unlikely to be attributable to a drug-related allergic response.

Physical Examination

If the allergist/immunologist is consulted during the reaction, performing a physical examination is critically important. This is particularly relevant if there is a rash present, and attention to the pattern and appearance of the rash as well as other concomitant signs will provide important information about the potential nature of the reaction. It is important to consider the presence of Nikolsky's sign (blisters and erosions appear when normal or erythematous skin in between lesions is rubbed gently) in SCARs. Also, the percent detachment of the skin is typically less than 10 percent of body surface in SJS, from 10 percent to 30 percent in overlap SJS-TEN, and greater than 30 percent in TEN.(45) In addition to the location, geography, and phenotype of the skin involvement, findings such as fever, mucosal involvement, photophobia, conjunctival erythema, respiratory distress, lymphadenopathy, liver or spleen enlargement, or joint involvement should always be investigated.

More commonly, however, the allergist/immunologist is consulted in the later stages of a reaction or after it has resolved. In this scenario, reviewing images of the reaction, potentially

obtained with the current plethora of cell phone cameras, would be invaluable. Examples of these include pictures of rash and/or angioedema, mucosal involvement, and joint swelling versus angioedema of the skin overlying the joint area. Physicians should remember to ask patients about objective documentation (i.e., photos), as patients may not always think to volunteer this information. Such documentation can be incorporated into the medical record with consent and protection of identity. In addition, using a camera to obtain such documents in case of future reactions should be discussed with all patients with drug allergy.(13-15)

Laboratory Tests: In Vivo and In Vitro

General tests may include a complete blood count with the differential focusing on eosinophil count, liver enzymes, and tryptase level. Elevated serum tryptase levels indicate both IgE- and non IgE-mediated mast cell/basophil activation. Levels above 11.4 ng/ml are considered abnormal. There is a linear association between tryptase levels and measures of reaction severity including the presence of hypotension.(46) Clinical symptoms of mast cell and/or basophil activation may be masked in patients premedicated with anti-histamines and/or steroids. In these cases an elevated tryptase level is an invaluable tool in identifying reaction-eliciting drugs, predicting future reactions, protecting patients from re-exposure, and providing a basis for desensitizations. Another tryptase level should be obtained after resolution of the reaction (baseline), as anaphylaxis can occur with normal acute tryptase, and comparing changes in a patient's tryptase levels to baseline is important, using the formula of a tryptase change $>1.2 \times$ baseline + 2. This will also help identify patients with systemic mastocytosis (elevated baseline tryptase levels) who are at risk for reactions when exposed to non-steroidal anti-inflammatory medications and opioids.(47-49) If tryptase remains elevated 4-6 weeks after an initial drug reaction including anaphylaxis, genotyping for the KITD816V mutation and a bone marrow biopsy are recommended to rule out a clonal mast cell disorder including systemic mastocytosis.

The signs and symptoms of the reaction will dictate more specific tests such as direct and indirect Coombs test for type II reactions and investigation of circulating immune complexes and complement levels for type III reactions. Other laboratory values including erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and urinalysis may be abnormal, suggesting a type III reaction. While they are non-specific tests, elevations in ESR and CRP may be seen in reactions with systemic features. In complex cases in which multiple drugs are involved without a clear-cut temporal relationship, or in cases with atypical skin lesions, obtaining a skin biopsy could prove useful. However, there are no absolute histologic criteria for the diagnosis of drug-induced eruptions, and a skin biopsy might not definitively exclude alternative causes. Liver biopsy is rarely indicated if the etiology of hepatitis in a patient taking one or more medications cannot be determined, as drug-induced hepatitis can have a distinct histologic pattern.(50)

Skin Testing for Evaluation of IgE-mediated hypersensitivity:

When the history suggests a potential IgE-mediated mechanism, skin testing (skin prick and intradermal testing read at 15-20 minutes) to the drug(s) should be considered. Histamine should

be used as positive control and saline as negative control. In the evaluation intradermal testing results, comparing the wheal size with the measurement obtained immediately after injecting the drug should be considered as the saline control wheal may fade and result in false diagnosis. In many cases, however, skin testing may not be feasible, not only because of the patient's general condition but also because of current administration of antihistamines or other medications which may interfere. In addition, it is best not to perform skin testing within the first 4-6 weeks following anaphylaxis due to the potential for mast cell mediator depletion that may temporarily lead to false-negative reactions. A refractory period for skin testing has been demonstrated in patients with perioperative anaphylaxis.(51) In vitro desensitization of human skin mast cells has demonstrated that at least 4-7 days are needed to restore full activating responses.(52) In a limited study of 25 cases of perioperative anaphylaxis, skin testing was performed at 2 time intervals, within 0-4 days, and 4-8 weeks later.(53) Twelve patients were positive in both periods, however 3 patients were only detected in the early time point, and 10 were detected in the late period. Hence in patients with severe conditions such as cancer, CF, or other disorders in which delaying treatment would adversely affect survival, skin testing may be performed 2-3 weeks after the initial hypersensitivity reaction, bearing in mind that a false negative result is possible.

A validated skin test protocol is currently only available for penicillin and beta-lactams. Non-irritating concentrations are available for other antibiotics as well.(54) Skin test protocols have been reported for a variety of other drugs as well. If the nonirritating concentration is not described in the literature or if the medication is new, skin testing starts with the standard (undiluted) concentration for prick (in non-vesicant medications and typically not exceeding 100 mg/mL) and 1/100 and 1/10 of that concentration for intradermal testing in conjunction with skin testing control subjects. In cases of anaphylaxis, the additional dilution of 1/1000 may be considered. Although this is a non-standardized approach with unknown specificity and sensitivity, if the concentrations prove to be non-irritating in control subjects, they may be of use in patients to help with diagnosing IgE sensitization.

Delayed Skin Test Readings and Patch Testing for Evaluation of Delayed Type Hypersensitivity:

Delayed skin test reading after intradermal drug injection, which can induce local inflammation and erythema at the site of injection at 24 hours later and up to 96 hours later, can be used to determine type IV sensitization and help predict reactions such as maculopapular exanthem (MPE).(55) The sensitivity and specificity of delayed intradermal skin test readings have not been established, but the test has been helpful in the diagnosis of non-severe delayed reactions induced by beta-lactam antibiotics, radiocontrast media, heparins, and biological agents.(56)

Patch testing with application of the drug allergens to the skin can be used to uncover drugs responsible for contact dermatitis and other type IV reactions.(56) Petrolatum is the recommended base for the dilution of the drugs (typically at 10% dilution), and the back is the

best test location in order to avoid accidental removal during daily activities.(57) Commercial reagents are available containing common contact allergens and provide high specificity for metal allergies. Commercial patch tests are not available for systemic drugs in the U.S. Patch testing has been used for MPE and severe cutaneous adverse drug reactions with systemic symptoms (SCARs), although its sensitivity is undetermined. Since there is potential concern about SCARs reactivation and/or significant localized reaction with patch testing, such testing should only be considered if multiple drugs are involved and/or the drug is the first line treatment option or there are no alternate medications available. In a study of 134 patients with delayed drug induced reactions, patch testing identified the culprit drug in 64% of DRESS cases, 58% of AGEP cases, but only 24% of SJS/TEN cases. It most frequently implicated carbamazepine and beta-lactams.(58)

Specific In-vitro Assays

A number of drug specific IgE tests are available including but not limited to ImmunoCAP[®] assays for penicillin G and penicillin V. However these assays have a low sensitivity, rarely play a critical role in patient evaluation and are not useful in diagnosing penicillin allergy in patients with remote histories of penicillin allergy.(59) Measuring specific IgE to platins including carboplatin, cisplatin, and oxaliplatin is a research tool with potential application in identifying reactors but requires further study.(60) In our expert opinion and review of published data, commercially available assays for drug reactions rarely play a critical role in the evaluation and management of patients.

The usefulness of other in vitro diagnostic tests, such as the basophil activation test (BAT), has been reported.(61) It should be noted that BAT is currently not commercially available. This test detects specific activation markers that are expressed on the surface of peripheral blood basophils following their incubation with the potentially responsible drug. At present, the most commonly used markers are CD63 and CD203c, and while their expression may help identify platin-sensitive patients, additional research is required. This said, BAT test can identify cancer patients with carboplatin allergy without the need for skin testing. It can be performed shortly after a patient's reaction and does not involve the risk of skin testing in those with severe anaphylactic reactions, and it holds potential as a diagnostic tool. Specificity and sensitivity are under investigation, and further validation will require studies in larger sample populations.

The lymphocyte transformation test relies on the activation and proliferation of T cells cultured in the presence of drug allergens. Reactivity is measured by ³H Thymidine incorporation after several days in culture or by ELISPOT or CSFE staining. These tests can be of value in type IV reactions but have not been standardized in such a manner to be useful in the field of drug allergy or to be commercially available.(62)

Genotyping is available for the screening of patients at risk for SCARs including SJS/TEN, such as HLA B*5701 for patients starting abacavir treatment and HLA-B*1502 for patients exposed to carbamazepine. Metabolic pathway analysis for cytochrome isoforms of the P450 pathway can

help identify patients with opioid intolerance, due to CYP2D6 deficiencies and other metabolic defects, that may place them at risk during surgery and anesthesia.(63) It should be noted that while many enzyme pharmacogenomic assays are available, their clinical utility is at this time debatable.

Drug Challenge

Understanding the clinical history and the potential risks of re-exposure is an important part of managing patients with drug hypersensitivity. Risk stratification is a process by which the physician reviews these risks and can then advise patients on optimal next steps. For example, a patient reporting a fine papular non-pruritic rash and no other clinical symptoms while being treated with amoxicillin in the setting of a viral infection is very unlikely to be allergic to amoxicillin. Instead, it is likely that the viral infection induced the exanthem and if re-exposed to amoxicillin the patient is unlikely to experience a rash. In contrast, a patient who reports recent symptoms of anaphylaxis requiring treatment with epinephrine during a carboplatin infusion is likely to be allergic to carboplatin. The Brown anaphylaxis criteria(64) is useful in risk stratification prior to desensitization and contains 3 grades, with grade 3 associated with changes in vital signs, syncope, or seizures and being of greatest severity (Table I).

The process of obtaining an informed consent is key to patient safety and is critically important to delivering quality patient care. The risks, benefits, and potential alternatives of all procedures should be discussed in detail with the patient and/or a pediatric patient's parents, and approval along with a signed consent form is recommended before proceeding.

Protocols

Drug challenge is considered the gold standard for the diagnostic evaluation of adverse drug reactions. This procedure is defined as the re-administration of a drug, usually with progressively increasing doses, to verify that a patient does not experience an adverse drug reaction. It is ideal to perform skin testing first whenever possible, particularly in cases where immediate reactions are being assessed and/or when the maximum non-irritating concentration for skin testing of the drug is known. Generally, drug challenge is subsequently performed in patients with negative skin testing. It can also, however, be used in the absence of prior skin testing based on the patient's history, especially if skin testing is not feasible or validated. Drug challenges should only be performed where immediate clinical support is available.

Graded challenges can usually exclude immediate hypersensitivity in patients with a low-risk history and allow for the evaluation of cross-reactivity of structurally-related compounds among different drug classes. This approach is not recommended for patients with a history consistent with a severe non-IgE-mediated reaction, or SCARs such as SJS, TEN, interstitial nephritis, hepatitis or hemolytic anemia.(13-15) If the history, skin test, and/or laboratory data suggest a mild non-IgE-mediated reaction or a reaction that was possibly unrelated, re-administration of the drug using a graded challenge procedure may be considered. Unlike desensitization

procedures, graded challenge does not modify a patient's immunologic reactivity. After a successful graded challenge and therapeutic course of the drug, future courses of the drug can be started without the need to perform another challenge. In contrast to desensitization, wherein patients receive incremental doses of a drug who have confirmed or highly-likely allergy, drug challenge is a diagnostic procedure that is performed in cases of low suspicion that a reaction is due to drug hypersensitivity. Graded challenge may be considered with caution for patients with serum sickness-like reactions (SSLRs), and it should be on an individual case basis that balances risks, benefits, and alternative approaches.

Drug challenges should be performed in a monitored clinical setting with rescue medications available in the event of a reaction. The decision to perform a drug challenge and location of the challenge, that is, in an outpatient clinic or in a more monitored setting, may be determined based on the patient's history, age, developmental maturity, current clinical condition, and skin testing.

Despite the widespread use of drug challenges, at present there are no evidence-based guidelines delineating the optimal number of steps. In a recent publication, Iammatteo et al. sought to determine the safety of test doses, or graded challenge, among patients with a history of adverse drug reactions.(65) A test dose could be considered either as synonymous with a typical, multi-step graded challenge or as a subset that consisted of one or two steps. A one-step test dose was defined as the administration of the full dose of a medication followed by a specific time period (i.e., 60 minutes) of observation. A two-step test dose was defined as $1/10^{\text{th}}$ of the full dose for a parenteral medication or $1/4$ of a pill for an oral medication followed by administration of the full dose after a specific period of observation. The authors compared the outcomes of one- or two-step test doses with multi-step graded challenges comprised of three or four steps performed during the same time period. They found that one- or two-step test doses were safe in appropriately selected, low-risk patients for the evaluation of adverse drug reactions. The overwhelming majority of test doses did not result in adverse drug reactions. Furthermore, when reactions did occur they were mild and often did not require treatment. Multi-step challenges do not seem to confer additional safety, but they may be performed depending on patient history or when caution is required, such as in those with anxiety or multiple co-morbid conditions. The starting dose for graded challenge is generally higher than for desensitization procedures and subsequent doses are usually administered in 10-fold dose increments in contrast to the 2-fold increments used in desensitization.

Time intervals between doses vary based on the type of potential reaction (i.e., immediate versus delayed), and they typically range from 30 to 60 minutes. A typical starting dose for graded challenge to a drug is $1/10^{\text{th}}$ of the target treatment dose, followed by $9/10^{\text{th}}$. The protocols for local anesthetics(66) and NSAID challenge generally involve more steps.(67) Other approaches should be considered to assess delayed reactions, which may require longer observation periods and/or uposing intervals anywhere from 24-48 hours to 7 to 14 days as described in the

literature. The route of administration may be oral, intravenous, subcutaneous, or intramuscular.(68, 69)

Additional education about test doses and drug challenge in patients who are unlikely to be allergic will expand the scope of practice, as many of these can be performed safely in an outpatient allergy clinic by trained staff.

Drug Desensitization Mechanisms

The term drug desensitization is defined as a procedure that modifies a patient's immune response to a drug, allowing temporary tolerance which can be maintained—as long as serum drug levels are maintained. This state is lost as soon as the drug is eliminated (2-3 half-lives). Desensitization protocols are specific for each drug and each patient and typically include more than 3 steps. The starting dose is approximately 1/10,000th of the final dose, with doses doubling at each increment until the target dose is attained.(3) Desensitization results in transiently reduced skin sensitivity to drug allergens in most patients with IgE-mediated reactions, and some become skin test negative by the end of the protocol.(70) The mechanisms by which temporary mast cell/basophil tolerance is induced during drug desensitization are not entirely clear. They are thought to be due to subthreshold doses of antigen that are not internalized and rearranged at the membrane and thus uncouple specific calcium responses.(71) Activation of inhibitory molecules preventing signal transduction and protecting against cell activation and the release of mediators involved in anaphylaxis has also been demonstrated in mast cells in vitro. The possibility that IgG antibodies may neutralize drug epitopes and serve a "blocking" function for IgE-dependent reactions has not been conclusively demonstrated, and maintaining drug desensitization state is dependent upon continuous exposure to the drug.(72)

Patients with an IgE-mediated drug allergy often respond well to desensitization procedures. However, similar desensitization procedures have been increasingly used with success in patients for whom evidence of IgE sensitization is lacking and who may have experienced direct mast cell/basophil activation through immune and non-immune related receptors.

Delayed reactions usually begin a few hours after exposure to the culprit drug and are typically classified as type IV reactions. The symptoms of delayed reactions are usually limited to the skin with maculopapular rashes. It should be noted that chemotherapy and monoclonal antibodies can also induce delayed reactions. These have features of Type I classification that occur hours to days after the infusion and are due to the prolonged systemic effects of premedications.

Desensitizations for type IV reactions have been performed with increasing frequency and success, although no standardized protocols are available. In many instances a patient's clinical history suggests allergy but there are limited objective data proving allergy before desensitization

is performed with success, and this presents a caveat to this scenario. Reactions that involve mucosal membranes and/or are associated with systemic symptoms are not amenable to desensitization due to the risk of inducing a severe systemic reaction similar to the initial reaction with even minuscule amounts of drug antigen.

The mechanism of delayed reactions is not fully understood. T cell activation has been evaluated in vitro following exposure to drugs inducing maculopapular rashes. CD4⁺ and CD8⁺ T cell sulfamethoxazole specific clones secreting IFN γ , IL-10 and IL-6 have been derived from cystic fibrosis patients presenting delayed rashes. Further study into these and other underlying mechanisms is required.

Principles and Procedures

Desensitization to a drug with validated skin testing should be considered if the patient has a positive skin test reaction and when no alternate treatment option is available, or when the drug is first line treatment and desensitization is not otherwise contraindicated. In the case of drugs for which no validated skin tests are available, desensitization may be considered regardless of the skin test result or even in patients with positive skin test, depending on the pattern of their initial drug-associated reaction.

Although desensitization is most successful if the history is strongly suggestive of an IgE-mediated reaction, as mentioned earlier it is also possible to perform desensitization for non-IgE-mediated immediate drug reactions including some type IV reactions.

Desensitization is not recommended for type II and type III serum sickness-like reactions and should NEVER be attempted in patients with histories of reactions including SCARs that involve significant skin desquamation such as EM, SJS or TEN. Even small doses of the drug may induce irreversible and potentially fatal recurrent desquamative reactions.(13-15, 73)

Immediate reactions begin suddenly, usually within minutes of initiation of the infusion in the case of intravenous or injected medication or within an hour of the intake of oral medications. Because chemotherapy drugs and monoclonal antibodies may be administered with anti-histamine and steroid premedication per national guidelines, acute reactions may happen later than one hour after the exposure. The signs and symptoms most typical for immediate-type allergic reactions include pruritus, flushing, urticaria, angioedema, throat tightening, wheezing, nausea, diarrhea, hypotension, syncope, and cardiorespiratory arrest that can lead to death.(9, 73-75) Atypical symptoms include back, chest or abdominal pain, chills, and fever (such as seen with taxenes, oxaliplatin, monoclonals such as rituximab, and intravenous iron preparations).(10, 76-80) These reactions result from the sudden activation of mast cells and/or basophils through IgE and non-IgE mechanisms, both of which respond to desensitization protocols.(9) Drugs

implicated in IgE-mediated allergic reactions include but are not limited to antibiotics such as penicillins and cephalosporins,(81) platinum-based chemotherapy agents (e.g., carboplatin, cisplatin, and oxaliplatin), taxenes including paclitaxel and docetaxel(60, 77) and monoclonal antibodies such as rituximab, cituximab, trastuzumab, and infliximab.(82)

If desensitization is being considered, appropriate specialists including those in infectious disease, rheumatology, oncology, and pulmonology should be consulted to help determine reasonable alternatives to the drug in question and/or that in fact the drug is first line treatment for the patient's condition. For example, if a patient has penicillin allergy with positive skin testing, is penicillin treatment requiring desensitization the optimal next step or are there reasonable alternative treatment options?

Similar to graded challenge, signed informed consent must be obtained and patients and/or a patient's parents or guardian should be informed that desensitization involves administration of a drug to which the patient is known or highly suspected to be allergic. Accordingly, there is substantial risk of at least a mild allergic reaction. Anaphylaxis is always a risk and is more common in highly sensitized patients or with aggressive dose escalations.

Drug desensitization should always be done in settings in which resuscitation personnel and resources are readily available. One-to-one nursing is required with a nurse who has been specifically trained to monitor desensitization protocols and recognize and treat allergic reactions, including the prompt administration of intramuscular epinephrine for anaphylaxis. Depending on the patient's history and whether this is the first desensitization or a repeat desensitization following one that was previously successful, the physical location may be an intensive care unit, inpatient floor, or outpatient infusion center. Patients with mild-moderate reactions can be desensitized in the outpatient setting under close observation by experienced and appropriately trained staff with readily available resuscitation medications, equipment and resources.(9, 82, 83) Patients with more severe reactions including grade 3 reactions should be desensitized in an intensive care unit. For patients with cardiac disease, those with restrictive or obstructive pulmonary diseases, and those for whom beta-blocker therapy cannot be easily discontinued for the procedure, desensitization should be performed in an intensive care setting. Desensitization in an intensive care setting is also most often preferable for the younger pediatric population, particularly in the case of first-time desensitizations. Young children have more limited and potentially less reliable communication skills than adults. This would also apply to older children with developmental issues and adults with the same. After an initial successful desensitization, repeat procedures may be performed in a carefully monitored outpatient center in the presence of appropriately trained staff.(9) The supervising physician should be available throughout the procedure and located within a few minutes of the desensitization site.

Drug desensitization can be performed in patients of any age and in pregnant women when

alternative therapies are not possible (e.g., for penicillin treatment in a penicillin-allergic woman with syphilis).(84-86)

Premedications, Types and Use

Pretreatment with H1 blockers, H2 blockers, antileukotrienes or leukotriene receptor antagonists, prostaglandin antagonists, and/or corticosteroids may be considered in selected cases, particularly in more difficult cases and those that are more likely to be non-IgE-mediated. Although clinical experience supports the use of premedication regimens to decrease the incidence, frequency and severity of reactions, formal clinical trials comparing premedication protocols are lacking. Premedications may not prevent IgE-dependent anaphylaxis, but they may help prevent and treat breakthrough reactions in cases of desensitization for suspected IgE-mediated drug allergy.(9, 87)

Protocols for immediate reactions

Protocols for drug desensitization have been successfully used for antibiotics, chemotherapy drugs, and monoclonal antibodies among other drugs in patients with IgE- and non-IgE-mediated hypersensitivity reactions. The most commonly used intravenous desensitization protocols are standardized 12- to 16-step protocols. The 12-step protocol is used for patients with initial reactions of grades I and II per the Brown anaphylaxis criteria(64) and assumed mild to moderate risk of adverse events during desensitization. The 16-step protocol is employed for patients with grade III reactions including anaphylaxis who are at higher risk during desensitization. Protocols shown (**Figure 2**) have been used successfully in adult patients with immediate hypersensitivity reactions to a variety of drugs including antibiotics, chemotherapy, monoclonal antibodies, and other drugs.(24, 70, 83, 88, 89) These protocols comprise 3 or 4 intravenous bags of a drug concentration that approximately doubles at each step up to a full concentration bag (1:1). The protocols have also been successfully used in the pediatric population, although in cases of desensitization to monoclonal antibodies younger patients seem to require more prolonged procedures with slower last step infusion rates.(90) In addition, desensitization to coagulation factors requires more prolonged protocols, likely due to the presence of inhibitor antibodies in these patients.(91, 92) A variety of other protocols have been described not only for intravenous desensitization but also for oral, subcutaneous, and intraperitoneal routes in both outpatient and inpatient contexts.(8, 9, 74, 81)

The main risk during a desensitization procedure is that of a recurrent immediate reaction and anaphylaxis when the patient is re-exposed to the culprit drug, but current data suggests that most breakthrough reactions are mild and less severe than the patient's initial hypersensitivity reaction. The authors are unaware of any published fatalities resulting from failed desensitization procedures, and they are considered to be safe procedures when no alternate treatment is available or the drug is first line treatment for the patient's condition.(9, 81)

Milder reactions can be treated with the same medications described above as premedications and the desensitization may be resumed, usually at a slower rate, after such mild breakthrough reactions. Rare delayed reactions have been reported following desensitization in patients who required high-dose or extended-duration therapy, including serum sickness, hemolytic anemia, thrombocytopenia, and nephritis.(93-95)

Once the patient has received at least one full dose after desensitization without further reactions, subsequent dosing may be administered with outpatient status, assuming proper patient education and the availability of epinephrine auto-injectors. If changes in dosing schedule are indicated for the patient's convenience, the medication can be administered earlier than a scheduled dose. This will maintain the temporary induction of tolerance state, as long as the new interval is not interfering with the steady state of the drug or potentially leading to drug toxicity. It is advised that these changes are made during inpatient status and that the patient is discharged on a strict dosing schedule.. Subsequent dosing should be administered on schedule and if there is a delay in administration and/or one or more doses are missed, then the patient may have to undergo desensitization again, particularly if the delay comprises more than two half-lives of the medication.(96)

Protocols for Delayed reactions (Figure 3)

Protocols for desensitization after mild delayed reactions include starting doses at 1/100000 to 1/100 the target dose. Each subsequent step doubles the dose at time intervals ranging from 30 minutes to 6 to 12 hours. These protocols span several days, and recent data suggest that some mild delayed reactions may be amenable to using protocols with shorter time intervals.(8, 9) Rapid graded challenge protocols similar to desensitization protocols (more than 3 doses at fixed time intervals) for trimethoprim sulfamethoxazole have been successful for delayed reactions.(97) Patients with delayed reactions without features of SJS/TEN can lose sensitivity over time, similar to those with IgE-mediated reactions, and it is possible that some of these patients may have had reduced sensitivity prior to desensitization. It is also possible that a rapid desensitization protocol targets T cell signal transduction as it targets mast cells and basophils.(71, 72, 98)

Decision Making and Best Practices for Drug Allergy: The Penicillin Pathway

Evidence suggests that patients lose allergic sensitivity to drugs over time and because reactions attributed to drug allergy may not be truly allergic, depriving patients of their first line therapy at the critical time of need is not optimal. Patients labeled as penicillin allergic when entering a hospital may suffer from unnecessary increased hospitalization days and infectious complications, and they may incur increased health care costs due to the use of a more expensive antibiotic.(99) Over the past few years, clinical practices and pathways have been developed to guide clinicians in addressing patients with a label of penicillin allergy who are in need of beta-lactam antibiotics.(100) With the goal of avoiding morbidity and mortality and providing safe first line antibiotic coverage, a Penicillin Pathway has been developed at Partners institutions in

Boston and other institutions nationwide. When time constraints do not allow for skin testing or alternative tests, the clinical history directs the decision making process according to type I reactions, type II-IV reactions, and mild reactions including delayed rashes. Alternative antibiotics, test dose procedure, and challenge and desensitization are recommended based on the presence of differentiating symptoms in the history and on risk stratification (Figure 4). It is mandatory that an allergist/ immunologist be involved in cases with high index of suspicion for type I reactions to provide recommendations and to perform appropriate measures including skin tests. It should also be noted that such an algorithmic approach, in avoiding penicillin and prescribing beta-lactams that may not be ideal alternatives, does not substitute for future penicillin allergy testing. This testing should still be performed at a non-emergent time in either the inpatient or an outpatient setting. Preliminary outcomes indicate that there have been no cases of SJS/TEN or anaphylaxis in the first 12 months of applying this clinical standard at one of the Partners hospitals based on its use in several hundred patients. The Pathway has also been translated into an application that can be viewed on a hand held device, and newer pathways for cephalosporin use have also been developed^{101, 102}.

References

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. *JAMA* 1998. p. 1200-5.
2. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International Consensus on drug allergy. *Allergy*. 2014;69(4):420-37.
3. Drucker AM, Pope EI, Field AE, Qureshi AA, Dumas O, Camargo CA, Jr. Association Between Maternal Pre-Pregnancy Body Mass Index, Gestational Weight Gain, and Offspring Atopic Dermatitis: A Prospective Cohort Study. *The Journal of Allergy and Clinical Immunology: In Practice*. 2019;7(1):96-102.e2.
4. Dioun AF. Management of multiple drug allergies in children. *Curr Allergy Asthma Rep*. 2012;12(1):79-84.
5. Saff RR, Camargo CA, Jr., Clark S, Rudders SA, Long AA, Banerji A. Utility of ICD-9-CM Codes for Identification of Allergic Drug Reactions. *The journal of allergy and clinical immunology In practice*. 2016;4(1):114-9 e1.
6. Aun MV, Blanca M, Garro LS, Ribeiro MR, Kalil J, Motta AA, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. *The journal of allergy and clinical immunology In practice*. 2014;2(4):414-20.
7. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, et al. Cellular and molecular pathophysiology of cutaneous drug reactions. *American journal of clinical dermatology*. 2002;3(4):229-38.
8. Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvao VR, Berlin ST, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. *The Journal of allergy and clinical immunology*. 2016;137(4):1154-64 e12.
9. Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. *The journal of allergy and clinical immunology In practice*. 2016.
10. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. *Journal of Emergency Medicine*. 2006;30(1):41-4.
11. Cromwell O, Pepys J, Parish WE, Hughes EG. Specific IgE antibodies to platinum salts in sensitized workers. *Clinical Allergy*. 1979;9(2):109-17.
12. Caiado J, Castells M. Presentation and Diagnosis of Hypersensitivity to Platinum Drugs. *Curr Allergy Asthma Rep*. 2015;15(4):15.
13. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. *The Journal of allergy and clinical immunology*. 127(3 Suppl):S60-6.
14. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. *American journal of clinical dermatology*. 2003;4(8):561-72.
15. Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, et al. Phenotype standardization for immune-mediated drug-induced skin injury. *Clinical pharmacology and therapeutics*. 2011;89(6):896-901.
16. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. *J Clin Invest*. 1988;82(6):1826-32.
17. Muraro A, Lemanske RF, Jr., Castells M, Torres MJ, Khan D, Simon HU, et al. Precision Medicine in Allergic Disease - Food Allergy, Drug Allergy, and Anaphylaxis-PRACTALL document

- of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. *Allergy*. 2017.
18. Park MA, Matesic D, Markus PJ, Li JT. Female sex as a risk factor for penicillin allergy. *AnnAllergy Asthma Immunol*. 2007;99(1):54-8.
 19. Dewachter P, Mouton-Faivre C, Castells MC, Hepner DL. Anesthesia in the patient with multiple drug allergies: are all allergies the same? *Curr Opin Anaesthesiol*.
 20. Foer D, Buchheit KM, Gargiulo AR, Lynch DM, Castells M, Wickner PG. Progestogen Hypersensitivity in 24 Cases: Diagnosis, Management, and Proposed Renaming and Classification. *The journal of allergy and clinical immunology In practice*. 2016;4(4):723-9.
 21. Prieto-Garcia A, Sloane DE, Gargiulo AR, Feldweg AM, Castells M. Autoimmune progesterone dermatitis: clinical presentation and management with progesterone desensitization for successful in vitro fertilization. *Fertil Steril*.
 22. Harper NJ, Dixon T, Dugue P, Edgar DM, Fay A, Gooi HC, et al. Suspected anaphylactic reactions associated with anaesthesia. *Anaesthesia*. 2009;64(2):199-211.
 23. Baldo BA, Fisher MM, Pham NH. On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspective. *Clin Exp Allergy*. 2009;39(3):325-44.
 24. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. *Gynecol Oncol*. 2005;96(3):824-9.
 25. Khoury L, Warrington R. The multiple drug allergy syndrome: a matched-control retrospective study in patients allergic to penicillin. *The Journal of allergy and clinical immunology*. 1996;98(2):462-4.
 26. Macy E. Multiple antibiotic allergy syndrome. *ImmunolAllergy ClinNorth Am*. 2004;24(3):533-43, viii.
 27. Galvao VR, Phillips E, Giavina-Bianchi P, Castells MC. Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation. *The journal of allergy and clinical immunology In practice*. 2016.
 28. Wang AL, Patil SU, Long AA, Banerji A. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy. *Ann Allergy Asthma Immunol*. 2015;115(5):422-8.
 29. Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. *New England Journal of Medicine*. 2003;349(17):1628-35.
 30. Pichler WJ, Srinoulprasert Y, Yun J, Hausmann O. Multiple Drug Hypersensitivity. *International archives of allergy and immunology*. 2017;172(3):129-38.
 31. Jenkins RE, Yaseen FS, Monshi MM, Whitaker P, Meng X, Farrell J, et al. beta-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis. *Chem Res Toxicol*. 2013;26(6):963-75.
 32. Parmar JS, Nasser S. Antibiotic allergy in cystic fibrosis. *Thorax*. 2005;60(6):517-20.
 33. Ramesh S. Antibiotic hypersensitivity in patients with CF. *Clin Rev Allergy Immunol*. 2002;23(1):123-41.

34. Wheatley LM, Plaut M, Schwaninger JM, Banerji A, Castells M, Finkelman FD, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. *The Journal of allergy and clinical immunology*. 2015;136(2):262-71 e2.
35. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. *ProcNatlAcadSciUSA*. 2005;102(11):4134-9.
36. Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. *Pharmacogenomics J*. 2014;14(3):281-8.
37. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. *Molecular diagnosis & therapy*. 2009;13(1):1-9.
38. Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. *AIDS*. 2005;19(9):979-81.
39. Khan DA, Solensky R. Drug allergy. *The Journal of allergy and clinical immunology*. 2010;125(2 Suppl 2):S126-37.
40. Bukacel DG, Bander R, Ibrahim RB. Cross-reactivity between paclitaxel and hazelnut: a case report. *J Oncol Pharm Pract*. 2007;13(1):53-5.
41. Kano Y, Mitsuyama Y, Hirahara K, Shiohara T. *Mycoplasma pneumoniae* infection-induced erythema nodosum, anaphylactoid purpura, and acute urticaria in 3 people in a single family. *J Am Acad Dermatol*. 2007;57(2 Suppl):S33-5.
42. Wu CC, Kuo HC, Yu HR, Wang L, Yang KD. Association of acute urticaria with *Mycoplasma pneumoniae* infection in hospitalized children. *Ann Allergy Asthma Immunol*. 2009;103(2):134-9.
43. Abonia JP, Castells M. Drug allergy in pediatric patients. *Pediatr Ann*. 2011;40(4):200-4.
44. Belchi-Hernandez J, Espinosa-Parra FJ. Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection. *AnnAllergy Asthma Immunol*. 1996;76(4):355-8.
45. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. *Arch Dermatol*. 2002;138(8):1019-24.
46. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. *New England Journal of Medicine*. 1987;316(26):1622-6.
47. Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. *The Journal of allergy and clinical immunology*. 2009;124(5):1047-54.
48. Sala-Cunill A, Cardona V, Labrador-Horrillo M, Luengo O, Estes O, Garriga T, et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients. *International archives of allergy and immunology*. 2013;160(2):192-9.
49. Borer-Reinhold M, Haeberli G, Bitzenhofer M, Jandus P, Hausmann O, Fricker M, et al. An increase in serum tryptase even below 11.4 ng/mL may indicate a mast cell-mediated

- hypersensitivity reaction: a prospective study in Hymenoptera venom allergic patients. *Clin Exp Allergy*. 2011;41(12):1777-83.
50. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. *Hepatology*. 2014;59(2):661-70.
51. Hepner DL, Castells MC. Anaphylaxis during the perioperative period. *Anesth Analg*. 2003;97(5):1381-95.
52. Zhao W, Gomez G, Macey M, Kepley CL, Schwartz LB. In vitro desensitization of human skin mast cells. *J Clin Immunol*. 2012;32(1):150-60.
53. Lafuente A, Javaloyes G, Berroa F, Goikoetxea MJ, Moncada R, Nunez-Cordoba JM, et al. Early skin testing is effective for diagnosis of hypersensitivity reactions occurring during anesthesia. *Allergy*. 2013;68(6):820-2.
54. Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. *Journal of Allergy and Clinical Immunology*. 2003;112(3):629-30.
55. Barbaud A. Skin testing in delayed reactions to drugs. *Immunol Allergy Clin North Am*. 2009;29(3):517-35.
56. Barbaud A. Skin Testing and Patch Testing in Non-IgE-Mediated Drug Allergy. *Curr Allergy Asthma Rep*. 2014;14(6):442.
57. Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. *Contact Dermatitis*. 2001;45(6):321-8.
58. Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. *The British journal of dermatology*. 2013;168(3):555-62.
59. Macy E, Goldberg B, Poon KY. Use of commercial anti-penicillin IgE fluorometric enzyme immunoassays to diagnose penicillin allergy. *Ann Allergy Asthma Immunol*. 2010;105(2):136-41.
60. Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, Oxaliplatin-, and Cisplatin-specific IgE: Cross-reactivity and Value in the Diagnosis of Carboplatin and Oxaliplatin Allergy. *The journal of allergy and clinical immunology In practice*. 2013;1(5):494-500.
61. Giavina-Bianchi P, Galvao VR, Picard M, Caiado J, Castells MC. Basophil Activation Test Is a Relevant Biomarker of the Outcome of Rapid Desensitization in Platinum Compounds-Allergy. *The journal of allergy and clinical immunology In practice*. 2016.
62. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. *Allergy*. 2004;59(8):809-20.
63. Agarwal D, Udoji MA, Trescot A. Genetic Testing for Opioid Pain Management: A Primer. *Pain Ther*. 2017;6(1):93-105.
64. Brown SG. Clinical features and severity grading of anaphylaxis. *Journal of Allergy and Clinical Immunology*. 2004;114(2):371-6.
65. Iammatteo M, Blumenthal KG, Saff R, Long AA, Banerji A. Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review. *The journal of allergy and clinical immunology In practice*. 2014;2(6):768-74.

66. Hepner DL, Castells MC, Tsen LC. Should local anesthetic allergy testing be routinely performed during pregnancy? *Anesthesia and Analgesia*. 2003;97(6):1853-4.
67. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. *Ann Allergy Asthma Immunol*. 2007;98(2):172-4.
68. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. *Allergy*. 2003;58(9):854-63.
69. Romano A, Gaeta F, Valluzzi RL, Caruso C, Alonzi C, Viola M, et al. Diagnosing nonimmediate reactions to cephalosporins. *The Journal of allergy and clinical immunology*. 2012;129(4):1166-9.
70. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. *Gynecologic Oncology*. 2004;95(2):370-6.
71. Sancho-Serra M, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization. *European Journal of Immunology*. 2011;41(4):1004-13.
72. Del Carmen Sancho-Serra M, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization. *Eur J Immunol*. 41(4):1004-13.
73. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. *Gynecologic Oncology*. 1994;53(1):121-2.
74. Galvao VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. *The journal of allergy and clinical immunology In practice*. 2015;3(2):175-85; quiz 86.
75. Picard M, Castells MC. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review. *Clin Rev Allergy Immunol*. 2015;49(2):177-91.
76. Levin AS, Otani IM, Lax T, Hochberg E, Banerji A. Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review. *The journal of allergy and clinical immunology In practice*. 2017;5(1):107-13 e1.
77. Banerji A, Lax T, Guyer A, Hurwitz S, Camargo CA, Jr., Long AA. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. *The journal of allergy and clinical immunology In practice*. 2014;2(4):428-33.
78. Banerji A, Rudders S, Clark S, Wei W, Long AA, Camargo CA, Jr. Retrospective study of drug-induced anaphylaxis treated in the emergency department or hospital: patient characteristics, management, and 1-year follow-up. *The journal of allergy and clinical immunology In practice*. 2014;2(1):46-51.
79. Bhargava P, Gammon D, McCormick MJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin. *Cancer*. 2004;100(1):211-2.
80. Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. *Cancer*. 2003;97(9):2301-7.
81. Turvey SE, Cronin B, Arnold AD, Dioun AF. Antibiotic desensitization for the allergic patient: 5 years of experience and practice. *Ann Allergy Asthma Immunol*. 2004;92(4):426-32.

82. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. *The Journal of allergy and clinical immunology*. 2009;124(6):1259-66.
83. Castells M. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. *The Journal of allergy and clinical immunology*. 2008.
84. Macy E. Penicillin skin testing in pregnant women with a history of penicillin allergy and group B streptococcus colonization. *Ann Allergy Asthma Immunol*. 2006;97(2):164-8.
85. Soriano V, Niveiro E, Fernandez J, Castello JV, Gonzalez P. Successful desensitization to penicillin after diagnostic reassessment. *Allergol Immunopathol(Madr)*. 2003;31(2):94-6.
86. Wendel GD, Jr., Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. *N Engl J Med*. 1985;312(19):1229-32.
87. Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. *Ann Allergy Asthma Immunol*. 2009;102(2):155-60.
88. Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT, et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. *The Journal of allergy and clinical immunology*. 2012;129(2):443-7.
89. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. *The Journal of allergy and clinical immunology*. 2009;123(6):1262-7 e1.
90. Dilley MA, Lee JP, Platt CD, Broyles AD. Rituximab Desensitization in Pediatric Patients: Results of a Case Series. *Pediatr Allergy Immunol Pulmonol*. 2016;29(2):91-4.
91. Dioun AF, Ewenstein BM, Geha RS, Schneider LC. IgE-mediated allergy and desensitization to factor IX in hemophilia B. *The Journal of allergy and clinical immunology*. 1998;102(1):113-7.
92. Platt CD, D'Angelo L, Neufeld EJ, Broyles AD. Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III von Willebrand disease (VWD). *The journal of allergy and clinical immunology In practice*. 2016;4(5):1006-8.
93. Arnold DM, Kukaswadia S, Nazi I, Esmail A, Dewar L, Smith JW, et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. *Journal of thrombosis and haemostasis : JTH*. 2012.
94. Cohen BA, Greenberger PA, Saini S. Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b. *Allergy and Asthma Proceedings*. 1998;19(2):85-8.
95. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. *Annals of Oncology*. 2003;14(12):1792.
96. Bonamichi-Santos R, Castells M. Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies. *Clin Rev Allergy Immunol*. 2016.
97. Pyle RC, Butterfield JH, Volcheck GW, Podjasek JC, Rank MA, Li JT, et al. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction. *The journal of allergy and clinical immunology In practice*. 2014;2(1):52-8.

- 947 98. Ang WX, Church AM, Kulis M, Choi HW, Burks AW, Abraham SN. Mast cell
948 desensitization inhibits calcium flux and aberrantly remodels actin. *J Clin Invest*.
949 2016;126(11):4103-18.
- 950 99. Macy E, Contreras R. Health care use and serious infection prevalence associated with
951 penicillin "allergy" in hospitalized patients: A cohort study. *The Journal of allergy and clinical*
952 *immunology*. 2014;133(3):790-6.
- 953 100. Blumenthal KG, Shenoy ES, Hurwitz S, Varughese CA, Hooper DC, Banerji A. Effect of a
954 drug allergy educational program and antibiotic prescribing guideline on inpatient clinical
955 providers' antibiotic prescribing knowledge. *The journal of allergy and clinical immunology In*
956 *practice*. 2014;2(4):407-13.
- 957 101. Blumenthal KG, Shenoy ES, Varughese CA, Hurwitz S, Hooper DC, Banerji A. Impact of a
958 clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin
959 allergy. *Ann Allergy Asthma Immunol* 2015; 115:294-300 e2.
- 960 102. Blumenthal KG, Wickner PG, Hurwitz S, Pricco N, Nee AE, Laskowski K, et al. Tackling
961 inpatient penicillin allergies: Assessing tools for antimicrobial stewardship. *J Allergy Clin*
962 *Immunol* 2017; 140:154-61 e6.
- 963 103. Absar N, Daneshvar H, Beall G. Desensitization to trimethoprim/sulfamethoxazole in HIV-
964 infected patients. *The Journal of allergy and clinical immunology* 1994; 93:1001-5.
- 965

FIGURE 1: Algorithm for Evaluation of Drug Hypersensitivity Reactions

- Absolute Contraindications: SCARs including Stevens Johnson Syndrome and other Bullous Dermatitis, Toxic Epidermal Necrolysis, DRESS syndrome, AGEP
- Grading: Based on Brown anaphylaxis criteria⁶⁴

FIGURE 2: A. Desensitization Protocol for Intravenous Medications (Carboplatin 500 mg) (Adapted from Sloane 2016⁹)

B. Desensitization to Methotrexate 1000 mg

FIGURE 3. Graded administration protocol for SMX/TMP (10 steps)*[§]


*Dosing interval is daily.

[§]Adapted from reference 103.

FIGURE 4: Penicillin Hypersensitivity Pathway¹⁰²

Table I. Severity grading system of immediate Hypersensitivity reactions. (Adapted from Brown)(64)

Grade	Severity	Description
1	Mild	Symptoms are limited to the skin (eg, flushing) or involve a single organ/system and are mild (eg, mild back pain).
2	Moderate	Symptoms involve at least 2 organs/systems (eg, flushing and dyspnea), but there is no significant decrease in blood pressure or oxygen saturation.
3	Severe	Symptoms typically involve at least 2 organs/systems, and there is a significant decrease in blood pressure (systolic <90 mm Hg and/or syncope) and/or oxygen saturation (<92%).



A.

Name of medication:		Carboplatin				
Target dose(mg):		500				
Standard volume per bag (mL):		250				
Final rate of infusion (mL/hour):		80				
Calculated target concentration (mg/mL):		2				
Volume		Concentration (mg/mL)		Total mg per bag	Amount infused (mL)	
Solution 1	250	mL of	mg/mL			
Solution 2	250	mL of	0.020	5.000		9.25
Solution 3	250	mL of	0.200	50.000		18.75
			1.984	496.065		250.00

PLEASE NOTE

The total volume and dose dispensed are more than the final dose given to patient because many of the solutions are not completely infused.

Step	Solution	Rate (mL/hour)	Time (minutes)	Volume infused per step (mL)	Dose administered with this step (mg)	Cumulative dose (mg)
1	1	2.0	15	0.50	0.0100	0.0100
2	1	5.0	15	1.25	0.0250	0.0350
3	1	10.0	15	2.50	0.0500	0.0850
4	1	20.0	15	5.00	0.1000	0.1850
5	2	5.0	15	1.25	0.2500	0.4350
6	2	10.0	15	2.50	0.5000	0.9350
7	2	20.0	15	5.00	1.0000	1.9350
8	2	40.0	15	10.00	2.0000	3.9350
9	3	10.0	15	2.50	4.9607	8.8957
10	3	20.0	15	5.00	9.9213	18.8170
11	3	40.0	15	10.00	19.8426	38.6596
12	3	80.0	174.375	232.50	461.3405	500.0000


Total time: 5.66 hours

B.

Name of medication:		Methotrexate			
Target dose(mg)		1000			
Standard volume per bag (ml)		250			
Final rate of infusion (ml/h)		80			
Number of bags		4			
Time per step		15 minutes			
Total numbers of steps		16 steps			
Standard time of infusion (hours)		6.6h			
Bag	Volume per bag (mL)	Concentration (mg/mL)	Total dose per bag (mg)		Amount of bag infused (mL)

1	250			0,002		0,500		9,38
2	250			0,040		10,000		9,38
3	250			0,400		100,000		18,75
4	250			3,968		992,106		250,00
Step	Bag	Rate (mL/h)	Time (min)	Cumulative time(min)	Volume infused per step(mL)	Dose administered with this step (mg)	Cumulative dose (mg)	Fold increase per step
1	1	2,5	15	15	0,625	0,001	0,001	2
2	1	5	15	30	1,25	0,003	0,004	2
3	1	10	15	45	2,5	0,005	0,009	2
4	1	20	15	60	5	0,010	0,019	2,5
5	2	2,5	15	75	0,625	0,025	0,044	2
6	2	5	15	90	1,25	0,050	0,094	2
7	2	10	15	105	2,5	0,100	0,194	2
8	2	20	15	120	5	0,200	0,394	2,5
9	3	5	15	135	1,25	0,500	0,894	2
10	3	10	15	150	2,5	1,000	1,894	2
11	3	20	15	165	5	2,000	3,894	2
12	3	40	15	180	10	4,000	7,894	2,485
13	4	10	15	195	2,5	9,921	17,815	2
14	4	20	15	210	5	19,842	37,657	2
15	4	40	15	225	10	39,684	77,341	2
16	4	80	174,375	399,375	232,5	922,659	1000,000	2

Step	Dose of SMX/TMP, mg/mg
1	2/0.4
2	4/0.8
3	8/1.6
4	16/3.2
5	40/8
6	80/16
7	160/32
8	320/64
9	400/80
10	800/160



HSR: Hypersensitivity Reaction

* Approval required